Tesamorelin, a synthetic peptide, stimulates growth hormone (GH) release from the pituitary gland. It modifies natural growth hormone-releasing hormone (GHRH) to enhance GH production. As a result, researchers study Tesamorelin for its potential to counteract GH decline and support metabolic health.
Moreover, Tesamorelin binds to GHRH receptors, triggering GH release from the anterior pituitary. This process, in turn, boosts fat metabolism, muscle growth, and protein synthesis. Additionally, Tesamorelin reduces visceral fat, thereby lowering risks for diabetes, heart disease, and obesity.
Furthermore, studies highlight Tesamorelin’s role in treating lipodystrophy by reducing excess visceral fat and improving insulin sensitivity. Researchers also explore its effects on body composition in individuals experiencing age-related GH decline.
Unlike traditional GH therapies, Tesamorelin stimulates natural GH release without introducing synthetic hormones. Consequently, this targeted approach helps regulate GH levels more effectively.
In addition, scientists investigate Tesamorelin’s effects on cognitive function, skin health, and aging. However, further research is still needed to confirm these benefits.
Overall, Tesamorelin remains a key research compound for metabolic health, fat loss, and GH regulation.